Tacabrutideg clinical trials
Also written BGB-16673.
How each study uses tacabrutideg is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tacabrutideg studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2025 (6); 1 more planned to start later
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2025 | 6 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 3
BeOne Medicines (7) · BeiGene (1) · Fred Hutchinson Cancer Center (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test tacabrutideg.
- Nov 2026A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy ParticipantsPhase 1 · BeOne Medicines
- Mar 2027A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell MalignanciesPhase 1/2 · BeOne Medicines
- Jun 2027Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-DegraderPhase 1/2 · BeOne Medicines
- Jul 2027A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Tacabrutideg (BGB-16673) in Participants With Moderate and Severe Hepatic ImpairmentPhase 1 · BeOne Medicines
Studies
Open first, then newest update. How each study uses tacabrutideg is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) InhibitorsRecruitingPhase 3BeOne MedicinesNCT06846671Written as Tacabrutideg
- A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Tacabrutideg (BGB-16673) in Participants With Moderate and Severe Hepatic ImpairmentNot yet recruitingPhase 1BeOne MedicinesNCT07856004Written as Tacabrutideg
- A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)RecruitingPhase 2M.D. Anderson Cancer CenterNCT07508995Written as BGB-16673
- Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Not yet recruitingPhase 2Fred Hutchinson Cancer CenterNCT07887061Written as Tacabrutideg
- Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-DegraderRecruitingPhase 1/2BeOne MedicinesNCT05294731Written as Tacabrutideg
- A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell MalignanciesRecruitingPhase 1/2BeOne MedicinesNCT05006716Written as Tacabrutideg
- A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingPhase 3BeOne MedicinesNCT06973187Written as Tacabrutideg
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy ParticipantsRecruitingPhase 1BeOne MedicinesNCT07005713Written as Tacabrutideg
- Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLLRecruitingPhase 2Massachusetts General HospitalNCT06849713Written as Tacabrutideg
- A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) InhibitorsActive, not recruitingPhase 3BeOne MedicinesNCT06970743Written as BGB-16673
- A Study of How [14C]-BGB-16673 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy ParticipantsCompletedPhase 1BeiGeneNCT06776679Written as [14C]-BGB-16673
Given beside what is tested · 2 — tacabrutideg is usual care or a partner of the new treatment
- A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell MalignanciesRecruitingPhase 1/2BeOne MedicinesNCT06634589Written as Tacabrutideg
- Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy ParticipantsCompletedPhase 1BeiGeneNCT06906809Written as BGB-16673
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
Codes
What other systems call tacabrutideg · ClinicalTrials.gg INT017577
- UNII (FDA) PF6GPZ4DYTTACABRUTIDEGOne source FDA
- NCI Thesaurus C215275TacabrutidegOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | PF6GPZ4DYT | TACABRUTIDEG | One source FDA |
| NCI Thesaurus | C215275 | Tacabrutideg | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.